Trade Allogene Therapeutics, Inc. - ALLO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.03 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023624% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001401% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.43 |
| Open | 1.36 |
| 1-Year Change | -88.32% |
| Day's Range | 1.35 - 1.42 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 2, 2025 | 1.43 | 0.14 | 10.85% | 1.29 | 1.45 | 1.29 |
| Apr 1, 2025 | 1.36 | -0.07 | -4.90% | 1.43 | 1.43 | 1.29 |
| Mar 31, 2025 | 1.44 | -0.04 | -2.70% | 1.48 | 1.48 | 1.37 |
| Mar 28, 2025 | 1.54 | -0.08 | -4.94% | 1.62 | 1.67 | 1.50 |
| Mar 27, 2025 | 1.54 | 0.00 | 0.00% | 1.54 | 1.56 | 1.48 |
| Mar 26, 2025 | 1.56 | -0.02 | -1.27% | 1.58 | 1.60 | 1.51 |
| Mar 25, 2025 | 1.58 | -0.09 | -5.39% | 1.67 | 1.67 | 1.58 |
| Mar 24, 2025 | 1.66 | -0.01 | -0.60% | 1.67 | 1.71 | 1.63 |
| Mar 21, 2025 | 1.61 | 0.03 | 1.90% | 1.58 | 1.62 | 1.52 |
| Mar 20, 2025 | 1.60 | -0.04 | -2.44% | 1.64 | 1.72 | 1.60 |
| Mar 19, 2025 | 1.68 | 0.02 | 1.20% | 1.66 | 1.71 | 1.52 |
| Mar 18, 2025 | 1.68 | -0.13 | -7.18% | 1.81 | 1.82 | 1.68 |
| Mar 17, 2025 | 1.83 | -0.08 | -4.19% | 1.91 | 1.91 | 1.81 |
| Mar 14, 2025 | 1.92 | -0.09 | -4.48% | 2.01 | 2.07 | 1.87 |
| Mar 13, 2025 | 1.87 | -0.15 | -7.43% | 2.02 | 2.07 | 1.83 |
| Mar 12, 2025 | 2.04 | 0.02 | 0.99% | 2.02 | 2.06 | 1.95 |
| Mar 11, 2025 | 2.02 | -0.05 | -2.42% | 2.07 | 2.10 | 1.86 |
| Mar 10, 2025 | 2.03 | -0.08 | -3.79% | 2.11 | 2.18 | 1.99 |
| Mar 7, 2025 | 2.16 | 0.12 | 5.88% | 2.04 | 2.30 | 2.04 |
| Mar 6, 2025 | 2.01 | 0.14 | 7.49% | 1.87 | 2.03 | 1.87 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com